National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

Found 467 cases where Vaccine targets Measles (MEA or MER or MM or MMR or MMRV) and Patient Died and Vaccination Date on/before '2018-11-30'

Case Details

This is page 23 out of 47

Result pages: prev   14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32   next


VAERS ID: 451473 (history)  
Form: Version 1.0  
Age: 45.0  
Sex: Female  
Location: Kansas  
Vaccinated:2012-01-16
Onset:2012-02-10
   Days after vaccination:25
Submitted: 2012-03-09
   Days after onset:28
Entered: 2012-03-12
   Days after submission:2
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MMR: MEASLES + MUMPS + RUBELLA (MMR II) / MERCK & CO. INC. 0952AA / 1 RA / UN
VARCEL: VARICELLA (VARIVAX) / MERCK & CO. INC. 0826AA / 1 LL / UN

Administered by: Other       Purchased by: Other
Symptoms: Cholecystectomy, Cholecystitis, Death, Herpes zoster, Rash, Respiratory failure, Skin lesion, Varicella, Varicella virus test positive, Viraemia
SMQs:, Anaphylactic reaction (narrow), Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (broad), Torsade de pointes, shock-associated conditions (broad), Hypovolaemic shock conditions (broad), Toxic-septic shock conditions (broad), Anaphylactic/anaphylactoid shock conditions (broad), Hypoglycaemic and neurogenic shock conditions (broad), Acute central respiratory depression (narrow), Infectious biliary disorders (narrow), Gallbladder related disorders (narrow), Guillain-Barre syndrome (broad), Hypersensitivity (narrow), Respiratory failure (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Hypokalaemia (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2012-02-19
   Days after onset: 9
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? Yes
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications: Unknown
Current Illness: End stage renal disease (ESRD); Lupus erythematosus; Transplant failure
Preexisting Conditions: Renal transplant
Allergies:
Diagnostic Lab Data: Cholecystectomy, 02/11/12; Serum varicella zoster, VZV positive
CDC Split Type: WAES1202USA04133

Write-up: Information has been received from a Doctor of microbiology and a licensed practical nurse (LPN) concerning a 45 year old female with end stage renal disease (ESRD), lupus, a history of renal transplant that was failing so patient was being considered for another one; who on an unspecified date, may have been vaccinated or exposed to someone who was vaccinated with a dose of VARIVAX (Merck) (manufacturer unknown) (lot number, dose and route not reported). The LPN reported that after much investigation it could not be determined if the patient had ever received a VARIVAX (Merck) (manufacturer unknown) or if she was exposed to chicken pox, and stated that the office would not have authorized or administered a live vaccine to a immunosuppressed patient. The Doctor of Microbiology reported that on 10-FEB-2012, the patient was admitted to the hospital with a diagnosis of cholecystitis. On 11-FEB-2012 a cholecystectomy was performed. On 15-FEB-2012, rash and skin lesions appeared. On an unspecified date, strain identification for samples was found to be varicella zoster virus (VZV) positive in the lab. The patient experienced respiratory failure on 19-FEB-2012 and died at 11:28 hours. The doctor of microbiology reported that there was "disseminated varicella" at time of death. The cause of death was respiratory failure secondary to herpes zoster viremia. It was unknown if an autopsy was performed (death certificate showed No for autopsy). Additional information has been requested.


VAERS ID: 453048 (history)  
Form: Version 1.0  
Age: 13.0  
Sex: Male  
Location: Unknown  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 2012-04-04
Entered: 2012-04-05
   Days after submission:1
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MMR: MEASLES + MUMPS + RUBELLA (MMR II) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Other       Purchased by: Other
Symptoms: Abscess drainage, Adenovirus test, Antibody test negative, Anticonvulsant drug level therapeutic, Bacterial test negative, Biopsy brain abnormal, Biopsy skin abnormal, Brain death, Brain oedema, CSF culture negative, CSF glucose decreased, CSF glucose normal, CSF lymphocyte count increased, CSF measles antibody negative, CSF monocyte count decreased, CSF protein increased, CSF protein normal, CSF virus no organisms observed, CSF white blood cell count increased, Central nervous system inflammation, Central nervous system lesion, Chills, Chronic granulomatous disease, Computerised tomogram head normal, Conjunctival hyperaemia, Conjunctivitis, Cryptococcus test, Cytomegalovirus test negative, Death, Demyelination, Electroencephalogram abnormal, Encephalitis, Encephalitis post measles, Enterovirus test negative, Eosinophilia, Epstein-Barr virus test negative, Eye pain, Fungal test negative, Graft versus host disease, Headache, Herpes simplex serology negative, Immunoglobulin therapy, Immunohistochemistry, Inflammation, Intensive care, Liver abscess, Lumbar puncture, Lumbar puncture abnormal, Lymphadenitis, Lymphocyte percentage, Medical induction of coma, Mental impairment, Microscopy, Monocyte percentage, Morbillivirus test positive, Mumps antibody test negative, Mycobacterium test negative, Nervous system disorder, Neurological decompensation, Neutropenia, Neutrophil percentage increased, Nuclear magnetic resonance imaging brain abnormal, Nuclear magnetic resonance imaging brain normal, Ophthalmological examination normal, Partial seizures, Photophobia, Polymerase chain reaction, Pyrexia, Rash, Rash erythematous, Rash pruritic, Red blood cells CSF positive, Staphylococcal abscess, Status epilepticus, Stem cell transplant, Viral test negative, Withdrawal of life support
SMQs:, Liver infections (narrow), Severe cutaneous adverse reactions (broad), Anaphylactic reaction (broad), Haematopoietic leukopenia (narrow), Neuroleptic malignant syndrome (broad), Systemic lupus erythematosus (broad), Anticholinergic syndrome (broad), Dementia (broad), Congenital, familial and genetic disorders (narrow), Convulsions (narrow), Malignancy related therapeutic and diagnostic procedures (narrow), Guillain-Barre syndrome (broad), Noninfectious encephalitis (narrow), Noninfectious encephalopathy/delirium (broad), Noninfectious meningitis (narrow), Hyponatraemia/SIADH (broad), Haemodynamic oedema, effusions and fluid overload (narrow), Glaucoma (broad), Optic nerve disorders (broad), Demyelination (narrow), Corneal disorders (broad), Eosinophilic pneumonia (broad), Retinal disorders (broad), Conditions associated with central nervous system haemorrhages and cerebrovascular accidents (broad), Conjunctival disorders (narrow), Ocular infections (broad), Skin tumours of unspecified malignancy (broad), Generalised convulsive seizures following immunisation (narrow), Hypersensitivity (narrow), Malignant lymphomas (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (narrow), Hypoglycaemia (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? Yes
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? Yes
Previous Vaccinations:
Other Medications: Unknown
Current Illness: Chronic granulomatous disease
Preexisting Conditions: Lymphadenitis; Liver abscess; Incisional drainage
Allergies:
Diagnostic Lab Data: Electroencephalography, Showed focal status epilepticus (epilepsia partialis continua) involving the right frontal cortex; magnetic resonance, No neurologic abnormalities were noted on brain; spinal tap, on day +43 was significant for glucose 43 mg/dL, protein 77 mg/dL, 51 WBCs/mm3 (88% lymphocytes, 8%; magnetic resonance, Brain MRI on day +45 showed bilateral patchy areas of cortical swelling and signal abnormality; diagnostic laboratory, Measles studies of the brain tissue were positive by reverse transcriptase-PCR for wild-type measle; brain biopsy, on day +53 demonstrated numerous eosinophilic intranuclear inclusion bodies and minimal perivascular; spinal tap, on day +49 showed less inflammation, with glucose 59 mg/dL, protein 54 mg/dL, 9 WBCs/mm3, and 294 re; cerebrospinal fluid, for bacteria, fungi, mycobacteria, and viruses were negative. Cryptococcal antigen was negative; enterovirus PCR, Negative; Epstein-Barr virus PCR, Negative; serum Herpes virus Ab, Polymerase chain reaction was negative; serum Herpes virus Ab, Polymerase chain reaction was negative; cytomegalovirus antigen, Antigenemia was negative; cerebrospinal fluid, No antibodies to measles, mumps, varicella, adenovirus, HSV-1/2, or lymphocytic choriomeningitis vir
CDC Split Type: WAES1203USA03678

Write-up: Information has been received from a physician, author of a literature article, title as stated above, concerning a 13 year old male patient who on an unspecified date, was vaccinated with a dose of MMR II (dose, route and lot number not reported). Measles inclusion body encephalitis (MIRE) was a disease of the immunocompromised host and typically occurred within 1 year of acute measles infection or vaccination. In addition to acute encephalitis and subacute sclerosis panencephalitis in immunocompetent hosts, measles virus could cause measles inclusion body encephalitis (MIBE) in immunocompromised hosts. MIBE presented typically with focal and intractable seizures within 1 year of initial measles infection. The mortality rate was high, and no effective treatment existed. The patient was a 13-year-old boy who received a diagnosis of X-linked chronic granulomatous disease (CGD) at 2 years of age after serratia lymphadenitis. The patient traveled frequently to urban, most recently 4 years before this illness. He received 1 documented MMR at one year of age, and had no history of a measles-like illness or measles exposure at any time. A second MMR was not documented. Despite prophylactic therapy for CGD with trimethoprim-sulfamethoxazole and thrice-weekly y-interferon, he had multiple staphylococcal liver abscesses that required extensive surgical drainage. Poor compliance with interferon was documented. Because of the severity of his repeated infections, SCT was performed. The conditioning regimen comprised fludarabine (180 mg/m2), busulfan (6.4 mg/kg), and equine anti-thymocyte globulin (ATG). Because of fever and chills after equine ATG, he received rabbit ATC for the last 3 days. On day -1, he began graft-verus-host disease (GVHO) prophylaxis with cyclosporine (CsA) and on day 0 with mycophenolate mofetil. He received anti-infective prophylaxis with oral acyclovir, itraconazole, intravenous vancomycin, and weekly CMV-immune globulin. On SCT day +10, he was admitted for fever and neutropenia and treated with broad-spectrum antibiotics. On day +11, a pruritic, erythematous rash developed, and his CsA dose was increased to treat presumed GVHD. Rash and low-grade fever persisted, and conjunctivitis and photophobia developed. Skin biopsy was consistent with GVHD; oral steroids were started with improvement in the rash. By day +19, he had engrafted with 99% donor chimerism by variable N-terminal repeats. On day +23, he presented with fever, headache, and eye pain. Head computed tomography scan and ophthalmologic examination were normal. Lumbar puncture showed 13 white blood cells (WBCs; 30% neutrophils, 52% lymphocytes, and 18% monocytes), glucose of 50 mg/dL, and protein of 34 mg/dL. Bacterial fungal and viral cultures were negative; cryptococcal antigen was negative. His symptoms improved, and he was discharged on day +27. By day +33, he had worsening erythematous rash on his face, arms, and trunk, and corticosteroids were increased to treat GVHD. On day +38, he was admitted to Hospital with afebrile focal seizures involving his left hand. Immunosuppressive medications on admission included CsA, mycophenolate mofetil, and prednisone. CsA was stopped and tacrolimus was started for possible CsA-induced seizures. The seizures progressed to involve his chin and tongue despite anticonvulsant therapy with clonazepam and valproic acid. Electroencephalogram showed focal status epilepticus (epilepsia partialis continua) involving the right frontal cortex. No neurologic abnormalities were noted on brain magnetic resonance imaging (MRI). He was transferred to the intensive care unit, where a continuous infusion of midazolam followed by a phenobarbital coma were unsuccessful in completely controlling seizures. Subclinical seizures persisted despite phenobarbital levels $g300 ug/mL. Lumbar puncture on day +43 was significant for glucose of 43 mg/dL, protein of 77 mg/dL, 51 WBCs/mm3 (88% lymphocytes, 8% monocytes, and 4% neutrophils), and 8 red blood cells/mm3. A repeat lumbar puncture on day +49 showed less inflammation, with glucose 59 mg/dL, protein 54 mg/dL, 9 WBCs/mm3, and 294 red blood cells/mm3. Spinal fluid cultures for bacteria, fungi, mycobacteria, and viruses were negative. Cryptococcal antigen was negative. Polymerase chain reaction (PCR) for herpes simplex virus (HSV) -1 and 2, human herpesvirus-6, enterovirus, Epstein-Barr virus, and arboviruses were negative. CMV antigenemia was negative. No antibodies to measles, mumps, varicella, adenovirus, HSV-1/2, or lymphocytic choriomeningitis virus were detected in the spinal fluid. Brain MRI on day +45 showed bilateral patchy areas of cortical swelling and signal abnormality, predominantly involving the frontal and temporal lobes, compatible with meningoencephalitis. A right frontal lobe lesion showed restricted diffusion. In retrospect, the initial MRI showed a small focus of signal abnormality in the right frontal cortex. Subsequent brain MRIs on day +49 and day +55 showed progressive involvement of the cerebral cortex and the basal ganglia. Treatment dose intravenous acyclovir was started on day +44 and was changed to intravenous gancyclovir on day +47. Brain biopsy on day +53 demonstrated numerous eosinophilic intranuclear inclusion bodies and minimal perivascular inflammatory reaction. Inclusions of varied sizes were seen in astrocytes, oligodendroglial cells, and neurons. Electron microscopic examination showed that the inclusions were clusters of relatively long, curved, tubular structures consistent with paramyxovirus nucleocapsids. Extensive demyelination of axons was seen. Immunohistochemistry for HSV-1/2, CMV, human immunodeficiency virus, adenovirus, and Epstein-Barr virus was negative. Measles studies of the brain tissue performed at the Centers for Disease Control and Prevention were positive by reverse transcriptase (RT)- PCR for wild-type measles virus, genotype D3, and by immunohistochemistry for measles nucleoprotein. Measles virus was isolated using the B95a marmoset lymphoblastoid cell line, and genotype D3 was confirmed by nucleotide sequence analysis of RT-PCR products. In addition, repeat skin biopsy on day +61 was consistent with GVHD. After demonstration of intranuclear inclusion bodies, intravenous ribavirin was initiated on day +57 (loading dose of 30 mg/kg, then 15 mg/kg every 6 hours for 16 doses, and then 7.5 mg/kg every 8 hours). Despite ribavirin and intensive supportive therapy, the patient''s neurologic status continued to deteriorate, and brain death was determined on day +70. Ribavirin was discontinued. Life support was stopped with the family''s agreement on day +92, and the patient died. No postmortem study was permitted. Immunohistochemistry and RT-PCR of the initial skin biopsy (day +15) were negative for measles virus. RT-PCR performed on the donor stem cells was negative for measles virus. MIBE occurred typically in immunocompromised patients within 1 year of measles infection. Patients usually presented with afebrile focal seizures and altered mentation. The seizures tended to be refractory to anticonvulsant therapy, and electroencephalogram often showed epilepsia partialis continua. The clinical features of the authors'' patient was consistent with this picture. Imaging studies such as brain MRI and computed tomography were often normal. Diagnosis required brain biopsy. The diagnosis of MIBE could be confirmed by RT-PCR for measles virus RNA or by immunohistochemistry. The prognosis was poor, with a 76% mortality rate, and all survivors manifesting significant neurologic sequelae. This case was unusual given the absence of apparent recent measles exposure or vaccination. The patient had not traveled outside during the year before SCT. The authors'' patient was born during the epidemic of 1989-1991 (birth year 1989) and had traveled only to foreign country, where the D3 genotype had not been endemic in recent years. An undiagnosed case of measles in the period 1989-1991 would suggest a latency period of 12 years, which was not typical of MIBE. The median length of time from acute measles infection or exposure to MIBE onset was 4 months. It was unlikely that the authors'' patient''s history of CGO placed him at increased risk for measles complications, but his SCT clearly did. The authors'' patient might have had a measles infection or exposure that was not recognized, although this was unlikely with his close medical supervision and prolonged hospitalizations the preceding year. The authors'' patient had a rash with conjunctival injection 27 days before the seizure onset, and skin biopsy suggested GVHO. The authors believed that the rash and conjunctivitis were not manifestations of measles because the skin biopsy obtained soon after rash onset was consistent histologically with GVHD, and immunohistochemistry and RT-PCR both were negative for measles virus. The authors also doubt that the stem cell donor was the source of measles infection as she had no history of measles-like infection or travel to an endemic area, and RT-PCR on the donor stem cells was negative for measles. MIBE had been reported 9 months after measles vaccination; however, the authors'' patient received the measles vaccination many years before SCT, and the identification of genotype D3 was inconsistent with the well-established vaccine virus genotype (vaccine genotype was genotype A). This case demonstrated the diagnostic utility of a brain biopsy in cases of encephalitis of unknown cause, particularly in immunocompromised individuals. Early brain biopsy might enable diagnosis and early institution of antiviral therapy. The utility of ribavirin or other therapies was unknown in MIBE. Ribavirin inhibits measles replication in vitro and had been used with some success to treat measles infections in immunocompetent hosts The authors'' patient, suggested the possibility of a long latency period between measles infection and onset of MIBE. The authors'' case illustrated the importance of early brain biopsy in cases of obscure encephalitis or encephalopathy in the immunocompromised host. Additional information has been requested.


VAERS ID: 453774 (history)  
Form: Version 1.0  
Age: 1.06  
Sex: Male  
Location: Massachusetts  
Vaccinated:2012-03-06
Onset:0000-00-00
Submitted: 2012-04-16
Entered: 2012-04-16
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HEPA: HEP A (VAQTA) / MERCK & CO. INC. 1416AA / 1 LA / IM
MMR: MEASLES + MUMPS + RUBELLA (MMR II) / MERCK & CO. INC. 0872AA / 1 LA / SC
VARCEL: VARICELLA (VARIVAX) / MERCK & CO. INC. 0977AA / 1 RA / SC

Administered by: Private       Purchased by: Public
Symptoms: Autopsy, Death
SMQs:

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2012-03-25
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: Albuterol/DUONEB (PRN)
Current Illness: None
Preexisting Conditions: Mild Persistent Asthma
Allergies:
Diagnostic Lab Data: None
CDC Split Type:

Write-up: Pt. received vaccines (MMR & Varicella) on 3/6/12. On 3/25/12 was found dead in crib (still waiting for autopsy results).


VAERS ID: 454298 (history)  
Form: Version 1.0  
Age: 1.0  
Sex: Female  
Location: Arkansas  
Vaccinated:2012-04-13
Onset:2012-04-14
   Days after vaccination:1
Submitted: 2012-04-25
   Days after onset:11
Entered: 2012-04-25
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HEPA: HEP A (HAVRIX) / GLAXOSMITHKLINE BIOLOGICALS AHAVB550AA / 1 LA / IM
HIBV: HIB (ACTHIB) / SANOFI PASTEUR UH157AA / 2 RA / IM
MMR: MEASLES + MUMPS + RUBELLA (MMR II) / MERCK & CO. INC. 1251AA / 1 RA / SC
PNC13: PNEUMO (PREVNAR13) / PFIZER/WYETH F22722 / 2 LA / IM
VARCEL: VARICELLA (VARIVAX) / MERCK & CO. INC. 1210AA / 1 LA / SC

Administered by: Public       Purchased by: Public
Symptoms: Autopsy, Death
SMQs:

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2012-04-14
   Days after onset: 0
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: none
Current Illness: none
Preexisting Conditions: asthma, overweight
Allergies:
Diagnostic Lab Data: An autopsy is being performed.
CDC Split Type: AR1207

Write-up: Child was found dead on the morning of 04/14/2012.


VAERS ID: 455297 (history)  
Form: Version 1.0  
Age: 1.3  
Sex: Male  
Location: Unknown  
Vaccinated:1982-05-01
Onset:0000-00-00
Submitted: 2012-05-09
Entered: 2012-05-10
   Days after submission:1
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MMR: MEASLES + MUMPS + RUBELLA (MMR II) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Other       Purchased by: Other
Symptoms: Death
SMQs:

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 1982-05-01
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: Unknown
Current Illness:
Preexisting Conditions: Unknown
Allergies:
Diagnostic Lab Data:
CDC Split Type: WAES1205USA00738

Write-up: Information has been received from a consumer, concerning a 16 month old brother, who approximately in May 1982 ("30 years ago"), was vaccinated with a dose of MMR II (Lot #, dose and route not reported). It was reported that approximately in May 1982 ("30 years ago") the patient died after getting a MMR II shot. The cause of death was unknown. It was reported to the Center for Disease Control. Additional information is not expected.


VAERS ID: 455358 (history)  
Form: Version 1.0  
Age: 1.03  
Sex: Male  
Location: Florida  
Vaccinated:2012-03-01
Onset:2012-03-05
   Days after vaccination:4
Submitted: 2012-03-26
   Days after onset:20
Entered: 2012-05-11
   Days after submission:46
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HIBV: HIB (PEDVAXHIB) / MERCK & CO. INC. 1531AA / 3 LL / IM
MMR: MEASLES + MUMPS + RUBELLA (MMR II) / MERCK & CO. INC. 0872AA / 1 LA / SC
PNC: PNEUMO (PREVNAR) / PFIZER/WYETH F18963 / 4 RL / IM
VARCEL: VARICELLA (VARIVAX) / MERCK & CO. INC. 0976AA / 1 RA / SC

Administered by: Public       Purchased by: Public
Symptoms: Autopsy, Death, Toxicologic test
SMQs:

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2012-03-05
   Days after onset: 0
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: LOTRIMIN cream BID - Rx written on 3/1/12
Current Illness: None
Preexisting Conditions: Eczema 3/1/12; Tinea corporis 3/1/12
Allergies:
Diagnostic Lab Data: None
CDC Split Type:

Write-up: Pt. died of unknown causes. Autopsy. Toxicology testing in process.


VAERS ID: 459278 (history)  
Form: Version 1.0  
Age: 0.27  
Sex: Male  
Location: Illinois  
Vaccinated:1990-05-07
Onset:0000-00-00
Submitted: 2012-07-14
Entered: 2012-07-14
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
DTP: DTP (NO BRAND NAME) / UNKNOWN MANUFACTURER - / UNK LG / IM
MMR: MEASLES + MUMPS + RUBELLA (NO BRAND NAME) / UNKNOWN MANUFACTURER - / UNK LG / IM

Administered by: Private       Purchased by: Other
Symptoms: Death, Pulse absent, Pyrexia, Respiratory arrest, Respiratory tract congestion, Resuscitation, Sudden infant death syndrome
SMQs:, Anaphylactic reaction (broad), Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (narrow), Acute central respiratory depression (narrow), Guillain-Barre syndrome (broad), Neonatal disorders (narrow), Hypersensitivity (broad), Respiratory failure (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 1990-05-08
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: Infant Tylenol
Current Illness: None
Preexisting Conditions: None
Allergies:
Diagnostic Lab Data:
CDC Split Type:

Write-up: On 05/07/1990 patient went to the Doctor and had a physical, which the doctor said he was in good health and doing well for his age and he also received 2 vaccinations MMR and DPT. He was congested and had a fever after receiving his shots. I gave him infant Tylenol during the day and before I put him to sleep. At 7am approximately 12 hours later I found patient in his bed not breathing and without a pulse. I performed CPR but patient died. The coroner determined that the cause of death was SIDS.


VAERS ID: 460432 (history)  
Form: Version 1.0  
Age: 1.28  
Sex: Female  
Location: New Jersey  
Vaccinated:2012-07-16
Onset:2012-07-22
   Days after vaccination:6
Submitted: 2012-07-27
   Days after onset:5
Entered: 2012-07-27
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HEPA: HEP A (VAQTA) / MERCK & CO. INC. 02771AE / 1 UN / UN
MMR: MEASLES + MUMPS + RUBELLA (MMR II) / MERCK & CO. INC. 1577 / 1 UN / UN
PNC13: PNEUMO (PREVNAR13) / PFIZER/WYETH E56178 / UNK UN / UN

Administered by: Private       Purchased by: Other
Symptoms: Acidosis, Acute myeloid leukaemia, Anaemia, Aspiration bone marrow abnormal, Bacterial test negative, Bilevel positive airway pressure, Blast cells present, Blood culture, Central venous catheterisation, Culture urine, Death, Diarrhoea, Endotracheal intubation, Full blood count abnormal, Hypercapnia, Leukocytosis, Mechanical ventilation, Oxygen saturation decreased, Postoperative respiratory distress, Pyrexia, Tachycardia, Tachypnoea, Thrombocytopenia, Vomiting
SMQs:, Anaphylactic reaction (broad), Acute pancreatitis (broad), Angioedema (broad), Asthma/bronchospasm (broad), Haematopoietic cytopenias affecting more than one type of blood cell (broad), Haematopoietic erythropenia (broad), Haematopoietic leukopenia (broad), Haematopoietic thrombocytopenia (narrow), Lactic acidosis (broad), Hyperglycaemia/new onset diabetes mellitus (broad), Neuroleptic malignant syndrome (broad), Systemic lupus erythematosus (broad), Anticholinergic syndrome (broad), Arrhythmia related investigations, signs and symptoms (broad), Pseudomembranous colitis (broad), Embolic and thrombotic events, venous (narrow), Blood premalignant disorders (narrow), Acute central respiratory depression (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Eosinophilic pneumonia (broad), Malignant lymphomas (broad), Myelodysplastic syndrome (broad), Noninfectious diarrhoea (narrow), Tumour lysis syndrome (broad), Respiratory failure (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Haematological malignant tumours (narrow), Infective pneumonia (broad), Dehydration (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2012-07-22
   Days after onset: 0
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications: (all medications received between admission 7/17/12 and death 7/22/12); Aluminum hydroxide suspension; Diphenhydramine; Acetaminophen; Propofol; Allopurinol; Cefepime; Ondansetron; Cytarabine; Morphine; Dexamethasone; Albuterol (inhaled); D
Current Illness: AML
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: Autopsy is pending
CDC Split Type:

Write-up: The patient had a screening CBC done the same day as vaccinations (7/16/12) that showed leukocytosis with blasts, anemia and thrombocytopenia. She was admitted to the hospital on 7/17/12. On 7/19/12, she was diagnosed with AML by bone marrow aspirate. She also started having fever and was started on broad spectrum antibiotics. Had surgical placement of CVC on 7/20/12 and received intrathecal cytarabine. She had postoperative respiratory issues, which was treated with high flow nasal cannula oxygen and diuretics. On 7/21/12, she received dexamethasone, cytarabine, daunorubicin and etoposide. Bortezomib (a tyrosine kinase inhibitor) was given per experimental treatment protocol. Beginning 7/21/12, she developed vomiting, diarrhea, tachypnea and tachycardia with worsening desaturations. She progressed over the course of the day on 7/22/12 despite increasing respiratory support from high flow nasal cannula oxygen to bilevel positive airway pressure, to endotracheal intubation with mechanical ventilation. The team caring for her was unable to increase oxygenation, improve carbon dioxide retention or correct acidosis. The patient died on 7/22/12 at 2151. Cultures from blood and urine did not grow bacteria. An autopsy is being done.


VAERS ID: 477186 (history)  
Form: Version 1.0  
Age: 1.06  
Sex: Female  
Location: Unknown  
Vaccinated:1994-11-01
Onset:1994-11-01
   Days after vaccination:0
Submitted: 2012-12-07
   Days after onset:6611
Entered: 2012-12-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MMR: MEASLES + MUMPS + RUBELLA (MMR II) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Other       Purchased by: Other
Symptoms: Blindness, Death, Immune system disorder, Pyrexia, Surgery
SMQs:, Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Glaucoma (broad), Optic nerve disorders (broad), Retinal disorders (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: 1993, Body temperature, 107-108 F
CDC Split Type: WAES1212USA001673

Write-up: This spontaneous report was received from the patient''s brother refers to a 13 months old female patient with no pertinent Medical History or Drug reactions/allergies who on unspecified date in approximately November 1994 (when the patient was 13 months of age) was vaccinated with MMR II (dose, lot number and route no reported). No other co-suspects were reported. No concomitant medications were reported. The night the patient received the vaccine, the patient developed a high fever (107-108 F) and was sent to an unspecified hospital where she was admitted and treated for an unspecified period of time. On unknown date, the patient had multiple unspecified surgeries, became blind and her "immune system failed." The patient was two years of age when she died (approximately in 1995). The outcome of the events patient developed a high fever (107-108 F), became blind and her "immune system failed" was unknown. The relatedness for the event and MMR II was unknown. Additional information is not expected.


VAERS ID: 494750 (history)  
Form: Version 1.0  
Age: 1.29  
Sex: Female  
Location: New York  
Vaccinated:2013-01-07
Onset:2013-01-07
   Days after vaccination:0
Submitted: 2013-06-20
   Days after onset:163
Entered: 2013-06-21
   Days after submission:1
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
DTAP: DTAP (INFANRIX) / GLAXOSMITHKLINE BIOLOGICALS AC14B155BA / UNK LG / IM
HEPA: HEP A (HAVRIX) / GLAXOSMITHKLINE BIOLOGICALS AHAVB667CB / UNK RL / IM
MMR: MEASLES + MUMPS + RUBELLA (MMR II) / MERCK & CO. INC. 0258AE / UNK RL / SC
VARCEL: VARICELLA (VARIVAX) / MERCK & CO. INC. H009535 / UNK LL / SC

Administered by: Unknown       Purchased by: Unknown
Symptoms: Death, Resuscitation, Sepsis
SMQs:, Agranulocytosis (broad)

Life Threatening? Yes
Birth Defect? No
Died? Yes
   Date died: 2013-01-16
   Days after onset: 9
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 2 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: 2013036599

Write-up: This medically confirmed spontaneous report (initial receipt 18-Jun-2013) concerns a female patient approximately 2 years old. Some time in January or February of 2013, the patient developed sepsis and subsequently passed away. The patient had received a flu shot (influenza vaccine, batch and manufacturer unspecified) prior to developing sepsis. The patient had been hospitalised (hospital information and duration unspecified) and CPR (cardiopulmonary resuscitation) had been conducted. The event outcome was fatal. Reporter''s comments: The reporter considered events serious due to hospitalisation, intervention to prevent serious criteria (CPR conducted), life threatening events (patient passed away) and death.


Result pages: prev   14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32   next

New Search

Link To This Search Result:

https://www.medalerts.org/vaersdb/findfield.php?EVENTS=ON&PAGENO=23&VAX[]=MEA&VAX[]=MER&VAX[]=MM&VAX[]=MMR&VAX[]=MMRV&VAXTYPES[]=Measles&DIED=Yes&VAX_YEAR_HIGH=2018&VAX_MONTH_HIGH=11


Copyright © 2019 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166